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Abstract
Background: The rapid spread of the 2009 H1N1 pandemic influenza virus (pH1N1) highlighted problems associated with
relying on strain-matched vaccines. A lengthy process of strain identification, manufacture, and testing is required for
current strain-matched vaccines and delays vaccine availability. Vaccines inducing immunity to conserved viral proteins
could be manufactured and tested in advance and provide cross-protection against novel influenza viruses until strain-
matched vaccines became available. Here we test two prototype vaccines for cross-protection against the recent pandemic
virus.
Methodology/Principal Findings: BALB/c and C57BL/6 mice were intranasally immunized with a single dose of cold-
adapted (ca) influenza viruses from 1977 or recombinant adenoviruses (rAd) expressing 1934 nucleoprotein (NP) and
consensus matrix 2 (M2) (NP+M2-rAd). Antibodies against the M2 ectodomain (M2e) were seen in NP+M2-rAd immunized
BALB/c but not C57BL/6 mice, and cross-reacted with pH1N1 M2e. The ca-immunized mice did not develop antibodies
against M2e. Despite sequence differences between vaccine and challenge virus NP and M2e epitopes, extensive cross-
reactivity of lung T cells with pH1N1 peptides was detected following immunization. Both ca and NP+M2-rAd immunization
protected BALB/c and C57BL/6 mice against challenge with a mouse-adapted pH1N1 virus.
Conclusion/Significance: Cross-protective vaccines such as NP+M2-rAd and ca virus are effective against pH1N1 challenge
within 3 weeks of immunization. Protection was not dependent on recognition of the highly variable external viral proteins
and could be achieved with a single vaccine dose. The rAd vaccine was superior to the ca vaccine by certain measures,
justifying continued investigation of this experimental vaccine even though ca vaccine is already available. This study
highlights the potential for cross-protective vaccines as a public health option early in an influenza pandemic.
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Introduction
Influenza virus is a significant public health concern, with the
average influenza season in the U.S. resulting in millions of cases
and tens of thousands of deaths [1]. These deaths occur despite
large-scale vaccination efforts, use of multiple antiviral influenza
drugs, and in-patient care. Pandemic influenza represents an even
greater concern. Current influenza vaccines function by targeting
hemagglutinin (HA). Seasonal vaccines are not useful when a
major antigenic change occurs in the circulating strain. Due to the
time required for manufacture of new strain-matched vaccines,
this can result in large proportions of the population being
unprotected during the initial pandemic wave.
This situation is exemplified by the 2009 H1N1 pandemic. The
2009 pH1N1 is believed to have originated in Mexico during
February of 2009 [2]. The virus soon spread to multiple countries,
with the first U.S. case identified in mid-April 2009. The WHO
officially declared an influenza pandemic in June. The time
required for vaccine manufacture, testing and distribution delayed
immunization in the U.S. until October, and initially restricted it
to high risk individuals due to limited supply. By this time,
infection rates were near peak levels. This delay occurred despite
rapid identification of the novel strain.
The 2009 pH1N1 experience has highlighted the need to
develop alternative vaccines operating by mechanisms of protec-
tion not dependent on antibodies against HA, the most variable
influenza virus antigen. Instead, vaccination can target conserved
antigens of influenza virus to generate heterosubtypic immunity
protective against diverse influenza A virus strains and subtypes.
While heterosubtypic immunity would not prevent infection,
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reduce the severity of illness and protect against lethal influenza
virus challenge. Such cross-protective vaccines could be prepared
and stockpiled prior to emergence of a pandemic virus, reducing
the time between identification of a novel threat and deployment
of the vaccine.
Various approaches to heterosubtypic vaccination against
influenza have been studied, using one or more of the conserved
viral proteins such as NP [3–6], matrix protein 1 (M1) or M2 [7–
9], or the viral polymerases [5]. Delivery systems for such vaccines
have utilized viral vectors [10], plasmid DNA [3], virus-like
particles [11], proteins [12], or peptides [13]. Heterosubtypic
immunity can be mediated by T cells and/or antibodies directed
against such relatively conserved antigens such as NP, M1, M2
and the HA stem [7].
We have previously demonstrated that prime-boost immuniza-
tion involving boosting with rAd expressing NP and M2 resulted in
protection against challenge with divergent influenza strains,
including virulent H1N1 and H3N2, and a highly pathogenic
H5N1 avian virus [14,15]. When the rAd vaccine was given
intranasally without priming, protection was rapidly induced, with
vaccinated animals protected from lethal challenge 2 weeks after a
single immunization, and was long-lasting, with protective
immunity still present 10 months after immunization [16].
While such vectored vaccines elicit potent immune responses
focused against a limited range of viral antigens (such as NP and
M2), to date they remain an experimental approach. An
alternative may be to utilize live-attenuated, ca influenza vaccines,
which are approved for human use and have been previously
demonstrated to induce heterosubtypic immunity [14,17,18]. The
ca and rAd-vectored vaccines can each be intranasally adminis-
tered, thus providing the advantage of immunity at a relevant
anatomic site.
In this study we have compared the effectiveness of NP+M2-
rAd vaccine and a 1977 ca vaccine against infection with the 2009
pandemic virus. We describe results of testing a single mucosally-
administered dose of these vaccines. We measured humoral and
cellular immune responses elicited by the vaccines which were
cross-reactive against pH1N1 antigens, as well as the ability of the
vaccines to rapidly achieve protection against pH1N1 challenge.
This study tests these vaccines against the recent pandemic H1N1
virus.
Methods
Ethics Statement
All animal protocols and procedures were approved by
Institutional Animal Care and Use Committees at the Center
for Biologics Evaluation and Research (protocol #1991-06) and
the University of Georgia (protocol# A3437-01) in animal
facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International. All
experiments were performed according to institutional guidelines.
Vaccines, viruses and peptides
Recombinant adenovirus vectors (Ad5-DE1DE3) expressing
influenza A or B nucleoprotein (kindly provided by Gary Nabel,
NIH Vaccine Research Center) and consensus M2 have been
described previously [8,19], and bulk stocks were produced by
ViraQuest, Inc. (North Liberty, IA). The ca viruses A/Alaska/6/
77 CR-29 clone 2 [H3N2], (A/Alaska ca), A/Hong Kong/123/77
CR-35 clone 2 [H1N1] (A/Hong Kong ca), and B/Ann Arbor/1/
86 CRB-117, clone 19-2 (B/AA ca) were generously provided by
Brian Murphy (NIAID, NIH, Bethesda, MD) and stocks were
produced in eggs as described previously [20]. The 2009 pandemic
H1N1 challenge virus is a mouse-adapted strain of A/California/
04/09 (ma-CA/04) [21]. Challenge stocks were grown in MDCK
cells for 48 hours at 37uC with 1 mg/ml TPCK-treated trypsin
(Worthington Biochemical Inc.; Lakewood, NJ). HA protein from
influenza virus A/California/04/09 (H1N1) was obtained through
the NIH Biodefense and Emerging Infections Research Resources
Repository, NIAID, NIH as a recombinant protein made in
baculovirus, NR-15258. Recombinant NP was purchased from
Imgenex (San Diego, CA) and has the A/PR/8/34 (PR8)
sequence. HIV p24 gag285–307 and PR8 M2e were synthesized
at the CBER core facility. All other PR8 and ma-CA/04 peptides
were purchased from GenScript (Piscataway, NJ).
Mice and immunizations
Six to eight week-old female BALB/cAnNCr (BALB/c) or
C57BL/6NCr (B6) mice were purchased from NCI and
maintained under specific pathogen-free conditions. Animals were
anesthetized with isoflurane and immunized intranasally with
50 ml of vaccine dropwise to the nares. Animals received a dose of
5610
9 virus particles (vp) each of NP-rAd and M2-rAd, or 1610
10
vp of B/NP-rAd, or 1610
5 50% tissue culture infectious doses
(TCID50) each of A/Alaska ca and A/Hong Kong ca,o r2 610
5
TCID50 of B/Ann Arbor ca.
Challenge infections
Mice were anesthetized with 250 ml of Avertin (2-2-2-tribro-
moethanol, Aldrich Chemical Co.; Milwaukee, WI) administered
via i.p. injection. Lethal doses (LD50) of ma-CA/04 were
determined for each mouse strain. Challenge experiments used 5
LD50 of ma-CA/04 administered intranasally in 50 ml. Animals
which lost $25% of their weight were humanely euthanized.
Animals for analysis of lung viral titers were chosen before the start
of the experiment. All challenge experiments were performed in
ABSL-3 facilities at the University of Georgia.
Antibody analysis
96-well flat bottom immunoplates (Nalge Nunc International;
Rochester, NY) were coated at 4uC overnight with 1 mg/ml of
recombinant NP (Imgenex; San Diego, CA) or 15 mg/ml of M2e
peptide in 0.125 M saline, 0.007 M borate buffer. For HA
ELISAs, recombinant H1 HA was diluted in PBS to 1 mg/ml for
plate coating. ELISA assays were performed as previously
described [22]. Optical densities (OD) were determined at
405 nm using a Multiskan EX spectrophotometer (Thermo Fisher
Scientific Inc.; Waltham, MA) and Ascent analysis software. Data
are expressed as endpoint titers, defined as the highest dilution of
sample giving an OD.3 standard deviations (SD) above the mean
of the starting dilution of naı ¨ve sera.
ELISPOT analysis
Lungs tissue was harvested and processed and interferon-c
ELISPOT was performed as previously described [8,15] by
stimulation with indicated peptides.
Determination of lung viral titers
For viral titer analyses, lungs were removed and placed into
2 ml Safe-Lock Tubes (Eppendorf AG; Hamburg, Germany)
containing 1 ml of PBS and a 5 mm diameter steel ball-bearing.
Lung tissue was homogenized using a TissueLyser (Qiagen;
Valencia, CA) for 2 minutes at 30 oscillations/second. Lung
homogenates were centrifuged at 2376 G for 5 minutes at 4uC and
the clarified supernatant aliquoted and stored at 280uC until used.
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density of 3610
4 cells per well (100 ml/well) the day before
infection. Lung homogenate supernatants were diluted in a 10-fold
series in quadruplicate using ‘Infection Media’ (MEM+2m ML -
glutamine+penicillin [100 IU/ml], streptomycin [100 mg/ml],
amphotericin B [0.25 mg/ml]+TPCK-treated trypsin [1 mg/ml]).
The cell monolayers were rinsed twice using PBS to remove all
serum-containing medium, and then 200 ml of diluted test sample
was added. Culture plates were then incubated at 37uC and 5%
CO2 for 72 hours. After incubation, 50 ml of supernatant was
removed for virus testing by hemagglutination. Fifty microliters of
0.5% chicken erythrocytes were added to supernatants in a 96-well
round bottom plate and incubated for 30–60 minutes. Wells were
observed for the presence of hemaggutination and TCID50 titers
calculated using the Reed and Muench method [23].
Graphs and statistics
All graphs were created using GraphPad Prism version 5
(GraphPad Software; La Jolla, CA). Statistics were performed
using SigmaStat version 3.1 (Systat Software, Point Richmond,
CA) or GraphPad Prism. Antibody and viral titer data were log-
transformed prior to statistical analysis.
Results
Sequence differences between ma-CA/04 and the
vaccines
Many studies of cross-protective vaccines have used a limited
number of laboratory virus strains. Here we assess the potential of
such vaccines against a recently emerged pandemic strain of direct
relevance to human health. Effectiveness of cross-protective
vaccination depends upon the impact of variation in key epitopes.
While NP and M2 are relatively conserved among influenza A
viruses, there are some potentially important differences between
the sequences in the vaccines and the ma-CA/04 challenge virus.
The dominant MHC class I NP epitopes recognized by BALB/c
and B6 T cells are NP147–155 and NP366–374, respectively [24–26].
Table 1 compares the amino acid sequences of these and other
epitopes tested in this study among the two vaccine sequences and
the ma-CA/04 challenge virus. Table 2 lists the peptides used in
this study. These peptides include segments of the NP and M2
proteins containing known or suspected MHC class I or MHC
class II epitopes for BALB/c or B6 mice.
Serum antibody levels following single dose vaccination
Mice were immunized once with rAd or ca viruses intranasally
and bled 3 and 5 weeks after immunization. BALB/c mice
immunized with NP+M2-rAd developed very high serum anti-NP
IgG titers by week 3 post-immunization (Fig. 1A) and maintained
a high level of antibody at week 5. Similarly, the ca vaccine elicited
high anti-NP IgG titers in BALB/c mice (Fig. 1A). Control
vaccines did not elicit detectable anti-NP IgG. The rAd and ca
vaccines both induced anti-NP antibodies in B6 mice, albeit with
lower titers (Fig. 1B).
BALB/c mice immunized with NP+M2-rAd developed a
robust serum anti-M2e IgG response by 3 weeks post-
immunization (Fig. 2A). We tested whether antibodies elicited
against the PR8 M2e vaccine sequence recognize the divergent
ma-CA/04 M2e sequence. Serum antibodies from immunized
mice recognized M2e peptides from both PR8 and ma-CA/04.
This robust anti-M2e response persisted through week 5 (Fig. 2B).
Animals immunized with the ca vaccine or control vaccines failed
to develop anti-M2e antibodies. When immunized with rAd and
ca vaccines, B6 mice developed no detectable serum anti-M2e
IgG at 3 weeks post-immunization (data not shown). Serum
antibodies from mice immunized with the ca vaccine failed to
cross-react with pandemic H1N1 HA above background levels
(Fig. S1).
Table 1. Sequence variation in vaccine and challenge virus epitopes.
Epitope Virus strain Sequence Accession # or Reference
NP55–69 A/PR/8/34 RLIQNSLTIERMVLS AAM75159
NP55–69 ma-CA/04 RLIQNSITIERMVLS [21]
NP55–69 *A/AA/6/60 RLIQNSLTIERMVLS AAA43451
NP147–155 A/PR/8/34 TYQRTRALV AAM75159
NP147–155 ma-CA/04 TYQRTRALV [21]
NP147–155 *A/AA/6/60 TYQRTRALV AAA43451
NP260–283 A/PR/8/34 ARSALILRGSVAHKSCLPACVYGP AAM75159
NP260–283 ma-CA/04 ARSALILRGSVAHKSCLPACVYGL [21]
NP260–283 *A/AA/6/60 ARSALILRGSVAHKSCLPACVYGP AAA43451
NP366–374 A/PR/8/34 ASNENMETM AAM75159
NP366–374 ma-CA/04 ASNENVETM [21]
NP366–374 *A/AA/6/60 ASNENMDTM AAA43451
M22–24 A/PR/8/34 SLLTEVETPIRNEWGCRCNGSSD AAM75162
M22–24 ma-CA/04 SLLTEVETPTRSEWECRCSDSSD [21]
M22–24 *A/AA/6/60 SLLTEVETPIRNEWGCRCNDSSD MFIV62
Sequence variations in known dominant NP T cell epitopes and M2e among influenza A viruses relevant to this study. Amino acids encoded by the challenge virus
which differ from the A/PR/8/34 sequence are underlined. Amino acids encoded by the challenge virus which differ from the A/AA/6/60 sequence are bolded.
*A/Ann Arbor/6/60 (A/AA/6/60) is the backbone virus of the ca viruses used in this study.
doi:10.1371/journal.pone.0021937.t001
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Given that some T cell epitopes differ in sequence between the
vaccine and the challenge virus, the T cell analysis was designed to
address the impact of these differences. We examined T cell
responses to NP and M2 of both the PR/8 and ma-CA/04
sequences using synthetic peptides containing previously reported
dominant or sub-dominant T cell epitopes (Fig. 3). Testing was
performed by IFN-c ELISPOT assays on cells from lung tissue 3
weeks after immunization, the timepoint of challenge in the
protection experiments.
As expected, BALB/c mice immunized with either NP+M2-rAd
or ca vaccine developed a strong response to the NP147–155 peptide
(Fig. 3A). These responses were stronger after immunization with
NP+M2-rAd than ca virus. It is worth noting that the NP147–155
sequence is 100% conserved between the rAd, ca, and challenge
virus strains. The T cell response to the PR8 M22–24 sequence was
moderate in lung cells from NP+M2-rAd-vaccinated mice, but
quite low in the group immunized with ca vaccine. A response to
the ma-CA/04 M22–24 sequence was not detected in any of the
BALB/c groups. While the MHC-II restricted T cell epitope in
Table 2. Peptides used in this study.
Virus
a Peptide
b Sequence Analyses
c
HIV p24 gag285–307 QGPKEPFRDYVDRFYKTLRAEQA B6+BALB/c
A/PR/8/34 NP147–155
d TYQRTRALV B6+BALB/c
A/PR/8/34 NP55–69 RLIQNSLTIERMVLS BALB/c
ma-CA/04 NP55–69 RLIQNSITIERMVLS BALB/c
A/PR/8/34 NP260–283 ARSALILRGSVAHKSCLPACVYGP B6
ma-CA/04 NP260–283 ARSALILRGSVAHKSCLPACVYGL B6
A/PR/8/34 NP366–374 ASNENMETM B6
ma-CA/04 NP366–374 ASNENVETM B6
A/PR/8/34 M22–24 SLLTEVETPIRNEWGCRCNGSSD B6+BALB/c
ma-CA/04 M22–24 SLLTEVETPTRSEWECRCSDSSD B6+BALB/c
NP and M2 peptides used in this study for analysis of immune responses. Amino acids in the challenge virus sequence which differ from the A/PR/8/34 sequence are
underlined. Amino acids in the challenge virus sequence which differ from the A/Ann Arbor/6/60 sequence are bolded.
aSource virus of the specified peptide.
bProtein and sequence range of the peptide.
cMice tested with the peptide.
dSequence is 100% identical in vaccine and challenge viruses.
doi:10.1371/journal.pone.0021937.t002
Figure 1. Anti-NP serum antibody titers. Anti-NP IgG levels in the serum of immunized mice at various timepoints following immunization.
BALB/c (A) or B6 (B) mice were immunized with 1610
10 TCID50 of NP+M2-rAd or B/NP rAd, 2610
5 TCID50 of A/Alaska ca+A/Hong Kong ca (Cold-
adapted) or B/AA ca, or left unvaccinated. Serum was obtained at 3 weeks (solid bars) or 5 weeks (open bars) post-vaccination and tested for anti-NP
IgG as described in Materials and Methods. Shown are the mean endpoint titers 6SD; n=5 per group. * P#0.05 versus naı ¨ve, { P#0.05 versus ca; One
Way ANOVA with Student-Newman-Keuls post-test.
doi:10.1371/journal.pone.0021937.g001
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BALB/c (A and B) mice were immunized as in Figure 1 or left unvaccinated. Serum was obtained at 3 weeks (A) or 5 weeks (B) post-vaccination and
tested for anti-M2e IgG antibody. Anti-M2e titers were determined using the PR8 peptide sequence (solid bars) and the ma-CA/04 peptide sequence
(open bars). Shown are the mean endpoint titers 6SD; n=5 per group. * P#0.0001 versus naı ¨ve, { P#0.05 versus ca; One Way ANOVA with Student-
Newman-Keuls post-test.
doi:10.1371/journal.pone.0021937.g002
Figure 3. Lung T cell responses. IFN-c responses of lung T cells following stimulation with peptides of vaccine sequences or challenge virus
sequences. BALB/c (A) or B6 (B) mice were immunized as in Figure 1, or left unvaccinated. Three weeks after immunization, T cell responses were
determined by IFN-c ELISPOT as described in Materials and Methods. Pooled lung cells were tested using cells from 5 (BALB/c) or 7 (B6) mice per
group. Shown are the mean of triplicate measurements of IFN-c secreting cells per million 6SD.
doi:10.1371/journal.pone.0021937.g003
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sequences differ by 5 residues, which seems to be sufficient to
eliminate any cross-reactivity. T cell responses to the PR8 NP55–69
sequences overall were very low but marginally higher in response
to the ma-CA/04 sequence.
Lung T cell responses were also examined for immunized B6
mice (Fig. 3B). The dominant NP MHC class I epitope recognized
by B6 CD8+ T cells, NP366–374, induced a relatively strong
response in NP+M2-rAd-immunized mice. The corresponding
peptide of ma-CA/04 contains a single amino acid mutation at
position 371 (M371V). It elicited a similar, albeit slightly lower,
response despite the fact that the mutation is located in the T cell
receptor (TCR) contact residue of the epitope. For mice
immunized with ca vaccine, there was a moderate response to
the PR8 NP366–374 peptide, but virtually none to the ma-CA/04
NP366–374 peptide. Moderate responses were observed with
NP260–283 peptides. The responses to the two sequence variants
were comparable, likely due to the fact that they differ by only one
residue at the C-terminus. The response to the NP260–283 peptide
was much greater with NP+M2-rAd vaccine than ca vaccine for
either sequence variant.
BALB/c and B6 mice are protected from challenge with
ma-CA/04
We next tested the ability of these partially cross-reactive
immune responses to protect against a mouse-adapted 2009 H1N1
pandemic influenza virus (Fig. 4). Mice were challenged with ma-
CA/04 three weeks after receiving a single dose of vaccine. All of
the NP+M2-rAd-immunized BALB/c mice survived challenge
(Fig. 4A) and experienced minimal weight loss (,12% weight loss;
Fig. 4B). Eight of the nine mice immunized with the ca vaccine
survived challenge, but experienced considerably greater morbid-
ity (,20% weight loss). All control animals died between days 6
and 8 post-infection. For B6 mice, 10 out of 12 animals
immunized with NP+M2-rAd and all animals in the ca vaccine
group survived challenge (Fig. 4C). Both the NP+M2-rAd and ca
groups lost weight at similar rates and with similar severities
(,15% weight loss; Fig. 4D). Surviving BALB/c and B6 mice
immunized with the ca vaccine began gaining weight one day
earlier than the NP+M2-rAd-immunized mice.
Lung viral titers
In order to monitor control of viral replication, lung viral titers
were measured at days 3 and 6 following challenge (Fig. 5). In
BALB/c mice, a single dose of NP+M2-rAd or ca virus reduced
lung challenge virus titers by approximately 100-fold at day 6 post-
challenge relative to naı ¨ve mice. No significant reduction in lung
virus titers was observed at day 3 in NP+M2-rAd-immunized
mice. In B6 mice, lung viral titers in the NP+M2-rAd group at day
6 were approximately 30-fold lower than in naı ¨ve mice (Fig. 5B).
Animals in the ca vaccine group had lung viral titers slightly lower
than naı ¨ve animals at day 6 but the difference was not statistically
significant. No significant differences in lung titers were observed
between any B6 groups at day 3 post-challenge. In either mouse
Figure 4. Weight loss and survival. Vaccine effectiveness in protection against challenge with ma-CA/04. Groups of BALB/c (A and B) or B6 (C and
D) mice were immunized as in Figure 1, or left unvaccinated. Three weeks after immunization, animals were challenged with 5 MLD50 of ma-CA/04
intranasally and monitored for survival (A and C) and weight loss (B and D). Weight loss graph shows average of n=9 (BALB/c) or n=12 (B6) mice
6SD. * P#0.0001 versus naı ¨ve; log rank test (A and C); or P#0.01 versus naı ¨ve; two-way repeated measures ANOVA with Holm-Sidak post-test (B and
D). No statistically significant differences were found between NP+M2-rAd and ca vaccine.
doi:10.1371/journal.pone.0021937.g004
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no significant difference from naı ¨ve mice at either time point.
Discussion
This study examined cross-protection against pH1N1 by
vaccines based on recombinant adenovirus and cold-adapted
influenza viruses given intranasally. Both vaccines protected two
strains of mice from lethal challenge with a mouse-adapted strain
of the 2009 pandemic H1N1 virus. Protective immunity developed
within three weeks of a single dose of each vaccine.
Although the cold-adapted vaccine we used in this study
contained an H1N1 virus along with the heterosubtypic H3N2, we
did not detect antibodies cross-reactive to the challenge virus HA
(Fig. S1). This indicates that antibody-mediated neutralization was
not responsible for protection. Serum antibody against M2e was
also absent in ca immunized mice (Fig. 2). Possible mechanisms of
cross-protection by ca vaccine include anti-NP antibodies present
in the serum (Fig. 1), anti-NP cell-mediated immunity (Fig. 3), and
cellular immunity to other components of the virus. Anti-NP
antibodies have been shown to protect mice against challenge [27–
29] as have T cells in the absence of antibody [30]. The relative
contribution to protection of these different mechanisms is
unknown.
In both C57BL/6 and BALB/c mice, we demonstrated that
immunization with ca viruses can protect from pH1N1 challenge
despite the mismatch between the HA and NA of the vaccine and
challenge viruses. This contrasts with a recent study in which a
seasonal commercial ca vaccine induced a significant NP-specific
cellular response in ferrets, but failed to protect them from
challenge with a 2009 pH1N1 isolate [31]. Both the ferret study
and that reported here used the same ca vaccine backbone. While
the dose of ca vaccine used in our experiments was clearly
sufficient to protect mice, CTL responses in the lungs of mice
immunized with ca virus have been shown to be highly dose
dependent [32]. In the ferret experiment, the dose of ca vaccine
recommended clinically for homologous protection was used, but
it is unknown if a higher dose would be necessary for cross-
protection. The discrepancy between the two studies may also be
due to biological differences between mice and ferrets.
Antibodies against M2e are non-neutralizing, but have been
shown to restrict virus growth in tissue culture and protect from
influenza challenge in vivo [8,11,33,34]. BALB/c mice developed
high levels of serum antibodies against M2e following NP+M2-rAd
but not ca vaccination. In confirmation of previous studies, B6
mice produced no M2e-specific antibodies with either immuniza-
tion. However, the M2-rAd component was included because our
previous studies have shown that immunization of B6 mice with
NP+M2-rAd provides superior protection to NP-rAd alone,
possibly due to a more robust T cell response [35]. While anti-
M2e antibodies likely contribute to reduced morbidity in rAd-
immunized BALB/c mice in our studies, they are not required for
protection from lethality. Interestingly, others have reported
induction of an M2e-specific antibody response by immunizing
B6 mice with a chimpanzee rAd vector expressing a concatamer of
3 copies of M2e linked to NP as a fusion protein [9]. In that
system, both anti-M2e antibodies and NP-specific CD8+ T cells
are required for protection of B6 mice. The requirements for
effective vaccination in B6 mice seem to vary depending on
specific conditions of the experiment including immunization,
vector, challenge strain and challenge dose.
For the conserved antigen NP, cross-reactive cellular immune
responses have been shown to play an important role in protection
[36]. The ma-CA/04 NP sequence is very similar (,92% amino
acid identity) to both the PR8 and A/Ann Arbor/6/60 NP
sequences. A few residues where the sequences diverge occur in
known T cell epitopes and the effect of those mutations on T cell
cross-reactivity could be very important for cross-protection.
NP366–374 is the dominant H2-D
b-restricted epitope recognized
by B6 mice. A single amino acid mutation at position 6 of this
epitope (M371V) differentiates the PR8 sequence used in the
NP+M2-rAd vaccine from the ma-CA/04 challenge sequence.
Residues 5 and 9 are MHC anchor residues, while 4, 6, and 7 are
TCR-contact residues [37,38]. Homology between the PR8 and
Figure 5. Lung viral titers. Viral replication in the lungs following ma-CA/04 challenge. BALB/c (A) or B6 (B) mice were immunized as in Figure 1, or
left unvaccinated. Three weeks after immunization, animals were challenged with 5 MLD50 of ma-CA/04 intranasally. Lung viral titers were determined
on day 3 (solid bars) and day 6 (open bars) by TCID50 assay as described in Material and Methods. Shown are the mean 6SD; n=4 per group.
*P #0.05 versus naı ¨ve; Kruskal-Wallis test with Student-Newman-Keuls post test. No statistically significant differences were found between NP+M2-
rAd and ca vaccine.
doi:10.1371/journal.pone.0021937.g005
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of cross-reactivity in IFN-c ELISPOT assays. Parallel T cell cross-
reactivity has been demonstrated with respect to the M371V
mutation in dual tetramer staining experiments [39].
A lesser degree of cross-reactivity to NP366–374 was observed for
mice immunized with the ca vaccine. The NP from the ca vaccine
is derived from A/Ann Arbor/6/60, the NP366–374 of which differs
from the challenge sequence at both positions 6 (M371V) and 7
(D372E). Although these are conservative mutations with respect
to the size and charge of the amino acids, two mutations in the
TCR contact residues seem sufficient to impair cross-reactive
recognition of the ma-CA/04 sequence by T cells. Dual tetramer
staining experiments showed similar patterns [39].
The T cell responses to the dominant epitopes in both BALB/c
and B6 mice were considerably greater following NP+M2-rAd
than ca immunization. The lower response induced by ca vaccine
could be due to differences in NP expression altering effective
antigen dose, increased antigenic competition in ca virus, or
augmentation of the immune response to rAd by adenovirus-
mediated toll-like receptor activation. Interestingly, despite the
lower T cell response, limited cross-reactivity to NP366–374, and
lack of M2e-specific antibody in B6 mice, ca immunized mice were
still protected from pH1N1 challenge.
There is considerable conservation of sequences identified as
human T cell epitopes among H1 and H5 viruses and previous
seasonal influenza strains. Studies have shown that human CD4
and CD8 T cells induced prior to the pandemic can cross-react
with multiple pH1N1 antigens, especially the matrix, NP, and
polymerase proteins [40,41]. Additionally, pre-pandemic T cells
recognizing conserved M1 epitopes can lyse pH1N1-infected
target cells, as well as produce TNF-a and IFN-c [42].
Similarly, multiple epitopes in internal antigens of H5N1
influenza viruses are recognized by T cells from individuals
living in regions where these viruses have not circulated [43].
Given this level of pre-existing immunity in the adult human
population, effective heterosubtypic vaccines may not need to
induce de novo immune responses, but might merely need to
b o o s tp r e - e x i s t i n gr e s p o n s e s .C ombined with our findings in this
study, this provides support to the concept of a practical, fast-
acting emergency vaccination regimen in the event of another
pandemic.
In humans, prior immunity might alter effectiveness of a
vaccine. Pre-existing antibodies to HA might in some cases
interfere with replication of seasonal ca vaccine strains. However,
some evidence suggests induction of CTL responses is still possible
despite the presence of neutralizing antibody to the vaccine strain
[44]. Pre-existing antibodies to adenovirus type 5 are common in
humans, and there is concern that they may block use of rAd
vectors. Possible methods to bypass pre-existing adenovirus
immunity include use of nonhuman adenovirus vectors [9] or
human adenoviruses of rare serotypes [45].
In this study we assessed protection at a relatively short interval
(3 weeks) following a single immunization, to demonstrate the
potential for emergency vaccination in response to a newly
emerging pandemic. A recent study has demonstrated that ca virus
is capable of protecting mice from pandemic virus 5 weeks after
immunization [46]. Others have shown protection can be induced
by ca vaccine as soon as 8 days following vaccination, albeit in a
non-pandemic challenge model [18]. While both rAd and ca
vaccines induced rapid T cell responses, the rAd vaccine was
superior to ca vaccine by the criteria of IFN-c secreting cells,
morbidity following challenge in the case of BALB/c, and viral
replication in the case of B6 mice. The better performance of the
rAd vaccine justifies continued study of this experimental vaccine,
even though ca vaccine is already available. We have shown
previously that NP+M2-rAd immunization induces antibodies, T
cell responses, and protection against highly virulent challenge
viruses persisting for at least 10 months, but the duration of
protection from the ca vaccine regimen used here is unknown.
The recent pH1N1 pandemic has highlighted the need for
effective public health interventions when the next influenza
pandemic emerges. The two candidate vaccines studied here
represent althernative approaches to achieving heterosubtypic
protection against pandemic influenza. Live attenuated influenza
vaccines are already approved for clinical use in most age groups.
While primarily intended to induce strain-matched immunity
against HA, the data reported here and elsewhere [14,17,18]
support the concept that they may also be valuable for inducing
cross-protective immunity against the conserved antigens of
influenza virus. Vectored vaccines (such as NP+M2-rAd) have
been demonstrated to provide strong and durable protection in
this and other animal studies [6,9,16,47,48], and some are in
investigational clinical trials [7]. While still experimental, they
were superior to ca vaccine by some measures in this study, and so
merit further investigation. Cross-protective vaccines could be
stockpiled prior to a pandemic and provide imperfect but valuable
immunologic defense for many months, until a strain-matched
vaccine could be manufactured and distributed in large quantities.
If deployed early in the course of a pandemic, conserved antigen
vaccines might reduce the human toll of morbidity and mortality,
and lower the concomitant economic impact and burden on
healthcare facilities and society.
Supporting Information
Figure S1 Immunization with ca does not induce cross-
reactive antibodies to pH1N1 HA. BALB/c and B6 mice
(n=5) were immunized with 2610
5 TCID50 of A/Alaska ca+A/
Hong Kong ca or B/AA ca as in Figure 1 or left unvaccinated.
Serum was obtained at 5 weeks post-vaccination from BALB/c
(solid bars) and B6 (open bars) mice and tested for the presence of
anti-pH1N1 HA IgG antibody. All serum samples were tested in
the presence of control monoclonal antibodies (hatched bars).
Shown are the mean endpoint titers 6SD; n=5 per group.
Positive control is H1N1 influenza A monoclonal antibody
mixture from the 2009–2010 WHO influenza detection kit (anti-
H1 mAb). Negative control is influenza B monoclonal antibody
from the 2009–2010 WHO influenza detection kit (anti-FluB
mAb).
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